HR (95% CI) | p Value | |
---|---|---|
Taper MTX | 0.744 (0.606 to 0.913) | 0.005 |
Female gender | 1.048 (0.662 to 1.268) | 0.628 |
RF positive | 0.922 (0.748 to 1.137) | 0.448 |
Erosions present | 1.393 (1.144 to 1.697) | 0.001 |
Age | 0.996 (0.989 to 1.003) | 0.250 |
Disease duration | 1.001 (0.988 to 1.014) | 0.874 |
Co-medication | 1.028 (0.866 to 1.220) | 0.751 |
Number of previous DMARDs | 1.048 (0.965 to 1.138) | 0.265 |
TNFi | ||
Infliximab (ref) | 0.000 | |
Adalimumab | 0.519 (0.406 to 0.662) | 0.000 |
Etanercept | 0.407 (0.317 to 0.522) | 0.000 |
DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; ref, reference variable; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitor.